Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US-10350181-B2 · Jul 16, 2019 · US
Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10722575B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10722575-B2 |
| Application number | US-201916425795-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 29, 2019 |
| Priority date | Nov 26, 2009 |
| Publication date | Jul 28, 2020 |
| Grant date | Jul 28, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the treatment of non-alcoholic steatohepatitis, comprising administering to a patient having non-alcoholic steatohepatitis a pharmaceutical composition comprising a therapeutically effective amount of 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. 2. The method according to claim 1 , wherein 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one is administered at a dose varying between 0.01 mg and 1 g per administration. 3. The method according to claim 1 , wherein 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one is administered at a dose varying between 1 mg and 100 mg per administration. 4. The method according to claim 1 , wherein 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one is administered at a dose of 80 mg to 1 g per administration. 5. The method according to claim 1 , wherein 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one is administered at a dose varying between 80 mg and 100 mg per administration. 6. The method according to claim 1 , wherein 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one is administered at a dose of 80 mg. 7. The method according to claim 1 , wherein the composition is administered to the patient once daily. 8. The method according to claim 1 , wherein the composition is administered to the patient orally. 9. The method according to claim 1 , wherein the composition is a tablet or a capsule. 10. The method according to claim 1 , wherein the composition is a tablet. 11. The method according to claim 1 , wherein the composition is a tablet comprising 80 mg to 1 g of 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one. 12. The method according to claim 1 , wherein the composition is a tablet comprising 80 mg to 1 g of 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one, said composition being orally administered to the patient once daily.
Assignees
Inventors
Classifications
- A61P1/16Primary
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title
Fatty acids · CPC title
Medicinal preparations containing organic active ingredients · CPC title
- A61K39/39Primary
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10722575B2 cover?
- The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating li…
- Who is the assignee on this patent?
- Genfit
- What technology area does this patent fall under?
- Primary CPC classification A61P1/16. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).